


# News Releases

All Years

Search

Go

[Advanced Search](#)



**OCT 12, 2021**

## **INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing**

 [Photos \(2\)](#)

**OCT 11, 2021**

## **Inhibrx To Host Webcast Presentation of Interim Results from the Phase 1 Trial of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency**

**SEP 13, 2021**

## **Inhibrx Announces Participation in Upcoming Investor Conference**

**AUG 9, 2021**

## **Inhibrx Reports Second Quarter 2021 Financial Results**

**JUN 21, 2021**

## **Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford**

**MAY 17, 2021**

## **Inhibrx Announces Participation in Upcoming Investor Conferences**

**MAY 13, 2021**

## **Inhibrx Reports First Quarter 2021 Financial Results**

**MAR 12, 2021**

## **Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist**

**FEB 1, 2021**

## **Inhibrx Announces Participation in Upcoming Investor Conference**

**JAN 13, 2021**

## **Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients**

Show  per page

